receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome. “These exciting results show atumelnant not only lowered key biomarkers ...

OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham are part of the Zacks Screen of the Week article.